This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:mp [03.13.2019] – [Data] sallieq | home:mp [05.26.2020] – [Laboratory tests] sallieq | ||
---|---|---|---|
Line 3: | Line 3: | ||
====== Marshall Protocol ====== | ====== Marshall Protocol ====== | ||
+ | |||
+ | < | ||
This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians. | This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians. | ||
Line 125: | Line 127: | ||
If these markers indicate dysfunction sustained for more than several months, we advising using [[home: | If these markers indicate dysfunction sustained for more than several months, we advising using [[home: | ||
+ | **//See also//** [[home: | ||
Line 250: | Line 253: | ||
Olmesartan will need to be [[home: | Olmesartan will need to be [[home: | ||
+ | |||
+ | {{tag>MP summary}} | ||
===== Data ===== | ===== Data ===== | ||
- | [[home: | + | [[home: |
[[home: | [[home: | ||
+ | ==== Recovery figures ==== | ||
+ | |||
+ | | ||
+ | |||
+ | SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91% | ||
+ | |||
+ | Sarcoidosis success 75.8% | ||
+ | |||
+ | Chronic Fatigue Syndrome success 60.1% | ||
+ | |||
+ | Lyme disease success 66.9% | ||
+ | |||
+ | Rheumatoid arthritis success 69.2% | ||
+ | |||
+ | Fibromyalgia success 64.2% | ||
+ | |||
+ | All Other Th1 disease success 59.8% | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||